Aberdeen Group plc Cuts Position in Krystal Biotech, Inc. $KRYS

Aberdeen Group plc decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 33.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 39,360 shares of the company’s stock after selling 20,012 shares during the period. Aberdeen Group plc owned about 0.14% of Krystal Biotech worth $9,704,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. EFG Asset Management North America Corp. boosted its stake in shares of Krystal Biotech by 18.4% in the third quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock valued at $4,784,000 after purchasing an additional 4,217 shares during the period. Voya Investment Management LLC grew its stake in shares of Krystal Biotech by 46.7% in the third quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock worth $16,578,000 after acquiring an additional 29,915 shares in the last quarter. Atle Fund Management AB grew its stake in shares of Krystal Biotech by 109.3% in the third quarter. Atle Fund Management AB now owns 42,191 shares of the company’s stock worth $7,448,000 after acquiring an additional 22,033 shares in the last quarter. William Blair Investment Management LLC grew its stake in shares of Krystal Biotech by 63.9% in the third quarter. William Blair Investment Management LLC now owns 149,302 shares of the company’s stock worth $26,356,000 after acquiring an additional 58,203 shares in the last quarter. Finally, Public Sector Pension Investment Board grew its stake in shares of Krystal Biotech by 15.9% in the third quarter. Public Sector Pension Investment Board now owns 100,431 shares of the company’s stock worth $17,729,000 after acquiring an additional 13,743 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Buying and Selling

In other news, Director Daniel Janney sold 37,895 shares of the company’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $266.88, for a total transaction of $10,113,417.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 12,500 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $272.14, for a total value of $3,401,750.00. Following the sale, the chief accounting officer owned 19,318 shares of the company’s stock, valued at $5,257,200.52. This trade represents a 39.29% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 129,164 shares of company stock worth $34,538,578. Insiders own 13.70% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have commented on KRYS. Jefferies Financial Group boosted their price target on shares of Krystal Biotech from $310.00 to $371.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Zacks Research downgraded Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Chardan Capital upped their price target on Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday, February 18th. HC Wainwright restated a “buy” rating and set a $310.00 price target (up from $240.00) on shares of Krystal Biotech in a report on Friday, January 9th. Finally, Citigroup lifted their price objective on shares of Krystal Biotech from $336.00 to $371.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $326.25.

Krystal Biotech Trading Up 0.8%

KRYS stock opened at $263.99 on Wednesday. The company has a market capitalization of $7.72 billion, a P/E ratio of 38.54 and a beta of 0.54. Krystal Biotech, Inc. has a twelve month low of $122.80 and a twelve month high of $298.30. The business has a 50 day simple moving average of $264.12 and a 200-day simple moving average of $235.64.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.The business had revenue of $107.11 million during the quarter, compared to the consensus estimate of $105.30 million. Research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.